Literature DB >> 23723314

Sixth joint meeting of J-CaP and CaPSURE--a multinational perspective on prostate cancer management and patient outcomes.

Hideyuki Akaza1, Shiro Hinotsu, Matthew R Cooperberg, Byung-Ha Chung, Ji Youl Lee, Rainy Umbas, Taiji Tsukamoto, Mikio Namiki, Peter Carroll.   

Abstract

This report summarizes the presentations and discussions that took place at the Sixth Joint Meeting of J-CaP and CaPSURE held in San Francisco, USA, in August 2012. The J-CaP and CaPSURE Joint Initiative was established in 2007 with the objective of analyzing, reviewing, comparing and contrasting data for prostate cancer patients from Japan and the USA within the two important large-scale, longitudinal, observational databases-J-CaP and CaPSURE. Since this initial collaboration between teams in the USA and Japan, the initiative has now expanded to include representatives of other Asian countries, several of whom have either established or are planning their own national prostate cancer databases. Several key topics were considered at this Sixth Joint Meeting including the current status of the J-CaP and CaPSURE databases and opportunities for collaboration with the more recently developed Asian prostate cancer databases. The latest comparative data from J-CaP and CaPSURE regarding outcomes following androgen deprivation therapy and combined androgen blockade were also reviewed. The possibility of a global chemoprevention trial to investigate the influence of soy isoflavones on prostate cancer incidence was considered. In addition, the ongoing debate regarding the role of screening and the use of active surveillance as a treatment option in the USA was discussed. The collaborators agreed that sharing of data and treatment practices on a global scale would undoubtedly benefit the clinical management of prostate cancer patients worldwide.

Entities:  

Keywords:  active surveillance; androgen deprivation therapy; chemoprevention; overall survival; prostate cancer; risk stratification

Mesh:

Substances:

Year:  2013        PMID: 23723314     DOI: 10.1093/jjco/hyt071

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  2 in total

1.  The Use of Androgen Deprivation Therapy (ADT) and Chemotherapeutic Agents in New Zealand Men with Prostate Cancer.

Authors:  Ross Lawrenson; Zuzana Obertová; Charis Brown; Peter Fong; Leanne Tyrie; Nina Scott; Michael Holmes
Journal:  J Cancer       Date:  2014-02-14       Impact factor: 4.207

Review 2.  Asian trends in primary androgen depletion therapy on prostate cancer.

Authors:  Hideyuki Akaza
Journal:  Cancer Biol Med       Date:  2013-12       Impact factor: 4.248

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.